Gallagher, Emily J. http://orcid.org/0000-0002-7920-8474
Moore, Heather http://orcid.org/0000-0002-0619-3267
Lacouture, Mario E.
Dent, Susan F.
Farooki, Azeez
Goncalves, Marcus D. http://orcid.org/0000-0002-0784-9248
Isaacs, Claudine http://orcid.org/0000-0002-9646-1260
Johnston, Abigail
Juric, Dejan http://orcid.org/0000-0003-2983-7704
Quandt, Zoe
Spring, Laura
Berman, Brian http://orcid.org/0000-0001-9872-5402
Decker, Melanie
Hortobagyi, Gabriel N. http://orcid.org/0000-0002-4873-4412
Kaffenberger, Benjamin H.
Kwong, Bernice Y.
Pluard, Timothy
Rao, Ruta
Schwartzberg, Lee
Broder, Michael S. http://orcid.org/0000-0002-2049-5536
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 30 June 2023
Accepted: 3 January 2024
First Online: 31 January 2024
Competing interests
: The authors declare no competing non-financial interests and the following competing financial interests: E.J.G.: consulting or advisory role with Novartis, Seattle Genetics, Flare Therapeutics and SynDevRx; H.M.: consulting or advisory roles with Novartis, Eli Lilly, Daiichi Sankyo, AstraZeneca, and Seattle Genetics; M.E.L.: consulting or advisory roles with Novocure, Janssen Research & Development, Roche, AstraZeneca, Genentech, Seattle Genetics, Lutris, Novartis, OnQuality Pharmaceuticals, Deciphera, Apricity Health, Relay Therapeutics, La Roche-Posay, Incyte, Tyra Biosciences, and Innovaderm; other relationship and stock/other ownership interests with Oncoderm (immediate family member); honoraria with Novartis, AstraZeneca, Deciphera, Seattle Genetics/Astellas, Novocure, Janssen, Roche/Genentech, Apricity Health, OnQuality Pharmaceuticals, Relay Therapeutics, RBC Consultants, MJH Associates, L’Oreal, Innovaderm, Nanology, Tyra Biosciences, Incyte, Lutris, and La Roche-Posay; research funding to author from US Biotest, Lutris, Paxman, Novocure; research funding to institution from AstraZeneca/MedImmune, Columbia University, National Jewish Health, and Novartis; an uncompensated relationship with Oncoderm; and an Open Payments link at ExternalRef removed; S.F.D.: consulting or advisory roles with Novartis and AstraZeneca; A.F.: consulting or advisory roles with Novartis; stock or other ownership interests in Johnson and Johnson; M.D.G.: consulting or advisory roles with Scorpion Therapeutics; stock or other ownership interests in Faeth Therapeutics; honoraria from Novartis, Pfizer, Scorpion Thera, and BridgeBio; patents, royalties, and other intellectual property with Weill Cornell Medicine; C.I.: consulting or advisory roles with Pfizer, Genentech/Roche, Novartis, Puma Biotechnology, Seattle Genetics, Sanofi/Aventis, Eisai, Ion Solutions, bioTheranostics, and AstraZeneca/MedImmune; patents, royalties, and other intellectual property with McGraw Hill Publishing, Wolters Kluwer, and Elsevier; other relationship with Side-Out Foundation; research funding to institution from Tesaro, Merck, and Seattle Genetics; A.J.: no interests to disclose; D. Juric: consulting or advisory roles with Novartis, EMD Serono, Eisai, Genentech, Ipsen, Syros Pharmaceuticals, MapKure, Vibliome Therapeutics, Petra Pharma, Relay Therapeutics, Silverback Therapeutics, and PIC Therapeutics; stock and other ownership interests in Relay Therapeutics, PIC Therapeutics, and Vibliome Therapeutics; research funding to institution from Novartis, Genentech, Takeda, Eisai, EMD Serono, Placon, Amgen, Syros Pharmaceuticals, InventisBio, Infinity Pharmaceuticals, Takeda, and Pfizer; Z.Q.: consulting or advisory role with Novartis; L. Spring: consulting or advisory roles with Novartis, Avrobio, and Puma; research funding to institution from Merck and Phillips; B.B.: consulting or advisory roles with Berg, Sensus, Aiviva, Pulse, Sirnaomics, Lemonex, Mediwound, Novan, Novartis, Biofrontera, Castle, Pfizer, Almirall, and Minolabs; speakers’ bureau with Sensus and Almirall; travel, accommodations, and expenses from Berg; stock and other ownership interest in Berg; research funding to institution from Sirnaomics; M.D.: Honorarium with Phar, LLC; G.N.H.: consulting or advisory role with AstraZeneca, Blueprint Medicines, Genentech, Novartis, and Seagen and research funding to institution from Novartis (unrelated to this abstract); B.H.K.: honorarium with Novartis; consulting or advisory roles with Eli Lilly, Novartis, and Novocure; research funding from Dermatology Foundation, Biogen, InflaRx, Eli Lilly, and Onquality; patents, royalties, or other intellectual property with ZitGenius; expert testimony for Emory Healthcare; B.Y.K.: consulting or advisory roles with Oncoderm and Novartis; T. Pluard: consulting or advisory roles with Pfizer, Macrogenics, Genentech, Seattle Genetics, Novartis, H3 Biomedicine, AstraZeneca/Daiichi Sankyo, and Gilead Sciences; speakers’ bureau with Genentech/Roche, Novartis, Seattle Genetics, and Gilead Sciences; research funding to institution from Seattle Genetics, Zymeworks, HiberCell, Pfizer, H3 Biomedicine, DAEHWA Pharmaceutical, G1 Therapeutics, Olema Pharmaceuticals, Dantari, AstraZeneca/Daiichi Sankyo, Orinove, and Sanofi; R.R. consulting or advisory roles with Novartis, AstraZeneca, Puma Biotechnology, Genentech/Roche, Seattle Genetics, and Immunomedics; L. Schwartzberg: employment, leadership, and stock or other ownership in OneOncology; speakers’ bureau with Seagen, Merck, and Pfizer; M.S.B.: relationships with Amgen, Bristol-Myers Squibb, Boston Scientific, Celgene, Dompe US, Eisai, Genentech, GRAIL, Greenwich Biosciences, Innovation and Value Initiative, Novartis, Otsuka, PhRMA Foundation, Prothena, Sanofi, Sunovion, Veana Therapeutics, Ackea Therapeutics, Biomarin, Exact Sciences, Genzyme, Jazz Pharmaceuticals, Mirum Pharmaceuticals, Recordati, Regeneron, and Takeda.